Harbinger Health raised $100 million in a Series B financing to support commercialization of its Resolve blood-based multi-cancer detection tests. The company said the portfolio is designed to reduce false negatives and false positives and provide actionable information about cancer tissue of origin using its Harbinger HX platform. Harbinger also described continued progress in PROCARES, a prospective multicenter validation study intended to establish clinical performance in patients undergoing evaluation for suspected cancer. The company reported that more than 88% of participants have been enrolled to date. If the validation results support clinical performance claims, Resolve would offer a new diagnostic workflow layer between suspicion and diagnosis across multiple cancer types, supported by an AI-driven approach to interpret blood-based signals.